了解阿尔茨海默病:分子机制和治疗策略
Sunny Rathee1,2, Vishal Pandey2, Sakshi Soni2
1College of Pharmaceutical Sciences (COPS), School of Health Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Ramanagara Dt., Bengaluru-562112, India.
Current Alzheimer research
|July 7, 2025
概括
阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病. 本综述探讨了AD的病理生理学,诊断和治疗方法,整合了当前的假设,以促进对这一日益增长的全球健康挑战的理解和促进合作解决方案.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 代表着一个显著和不断升级的全球健康问题,主要是由于增加预期寿命和人口老龄化.
- 阿尔茨海默病的多因素性质,受遗传和环境因素的影响,对理解它的起源提出了复杂的挑战.
研究的目的:
- 综合审查阿尔茨海默病 (AD) 的病理生理学.
- 评估目前对AD的诊断进展和治疗策略.
- 综合流行病学趋势,分子机制和临床试验结果,以指导未来的研究和临床实践.
主要方法:
- 综合AD病理生理学当前假设的文献综述 (粉样层次,病理,神经炎症等). ) 的情况.
- 诊断生物标志物的批判性评估,用于早期检测和监测.
- 对治疗方法的评估,包括抗粉样蛋白/抗陶策略,干细胞疗法和纳米生物技术.
主要成果:
- 该评论整合了解释AD病理生理学的多个假设,突出了其复杂和多因素的病因.
- 诊断方面的进步主要集中在生物标志物识别上,用于早期检测和疾病进展监测.
- 治疗策略包括已建立的抗粉样蛋白和抗tau方法,以及新的干细胞和纳米生物技术干预措施.
结论:
- 对AD的全面理解需要整合各种病理生理机制,遗传倾向和环境因素.
- 通过生物标志物的早期检测和多方面的治疗干预措施对于管理AD至关重要.
- 持续的研究和合作对于开发针对阿尔茨海默病的变革性解决方案至关重要.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.N-甲基-D-阿斯巴甜酸盐受体. 甲基-D-阿斯巴甜酸盐受体.乙胆化酶抑制剂 乙胆化酶抑制剂粉样蛋白前体蛋白质是粉样蛋白的前体.亚脂蛋白 E 是一种非脂蛋白 E.更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.4K
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
01:15Parkinson's Disease: Overview
716
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
01:30Dementia
173
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
173
01:24Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
03:03Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K